1021.html
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Mon, 10 Mar 2025 00:41:00 GMT
"The dosing of our first patient with IM-1021 advances that mission, as we work to establish safety and explore efficacy of IM-1021 in patients with high unmet need in B-cell lymphomas and solid ...